Pre-meal Consumption of Whey in Gestational Diabetes Mellitus From Diagnosis to Delivery
Primary Purpose
Gestational Diabetes
Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Whey
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Gestational Diabetes
Eligibility Criteria
Inclusion Criteria:
- GDM (OGTT level of blood glucose ≥ 9 mmol/L)
- Normal blood pressure
- Age > 18 years
Exclusion Criteria:
- Special dietary regimes > 1 month at time of inclusion e.g. ketogenic diet
- Daily intake of protein supplements
- Milk allergy or phenylketonuria
- Medication with effect on glucose metabolism e.g. steroids
- Do not speak or understand Danish
- Twin pregnancy
- PCOS
- PI finds the patient unfit (like mental illness, too nervous or other)
- Severe chronic illness
- Severe nausea/vomiting
- Non-breakfast eaters
- Celiac disease
The initiation of insulin treatment during the trial will not lead to exclusion from the trial.
Sites / Locations
- Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Whey
Placebo
Arm Description
Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
Outcomes
Primary Outcome Measures
Maternal glycemic variability (GV)
The Coefficient of Variation, power: n = 50
Maternal glycemic variability (GV)
Interquartile range (IQR), power n = 40
Maternal glycemic variability (GV)
Standard deviation (SD), power n = 18
Secondary Outcome Measures
24 hours interstitial fluid glucose measures
Continuous glucose monitoring
mean glucose
Continuous glucose monitoring
maximum glucose
Continuous glucose monitoring
Interstitial fluid glucose concentrations
Continuous glucose monitoring
Total energy expenditure
Measured with a combined accelerometer and heart rate monitor, reported in kcal
Activity energy expenditure
Measured with a combined accelerometer and heart rate monitor, reported in kcal
Activity count
Measured with a combined accelerometer and heart rate monitor, reported in counts
Heart rate
Measured with a combined accelerometer and heart rate monitor, reported in beats per minute
Resting energy expenditure (REE) (Resting Metabolic Rate)
Indirect calorimetry
Respiratory quotient (RQ)
Indirect calorimetry
Oxidation rates of lipid, carbohydrate and protein
Indirect calorimetry
Diet diary
Total energy intake, composition of macronutrients
Self-reported appetite
Questionnaire: A numerical rating scale ranging from "not at all = 0" to "extremely = 10" will be used to assess Hunger, Fullness, Satiety, Desire, Prospective consumption (Quantity).
Body Mass Index
weight and height will be combined to report BMI in kg/m^2
Gestational weight change
Medications
number of participants prescribed insulin, dose of insulin, time to insulin. Methyldopa, nifidipin or labetalol (medication to lower blood pressure)
Pregnancy data
Number of participants with hypertension, preeclampsia, maternal weight gain
Delivery data
Number of patients with cesarean section, shoulder dystocia, induction of labour
Non-targeted metabolomics will be performed on a sample of breast milk using Nuclear Magnetic Resonance
Analysis generating metabolites from pathways on amino acids, peptides, carbohydrates and lipids measured in folds increase/decrease when comparing placebo with whey
Blood pressure
Systolic and diastolic blood pressure
Concentration differences in Insulin like growth factor I (IGF-1) (mother)
Concentration differences in IGF-binding protein 3 (IGFBP-3) (mother)
Concentration differences in IGF-binding protein 1 (IGFBP-1) (mother)
Concentration differences in FGF-21 (mother)
Concentration differences in Leptin (mother)
Concentration differences in Adiponectin (mother)
Concentration differences in CRP (mother)
Concentration differences in Prolactin (mother)
Concentration differences in Cortisol (mother)
Concentration differences in Insulin (mother)
Concentration differences in Free Fatty Acids (mother)
Concentration differences in lactate (mother)
Concentration differences in grehlin (mother)
Concentration differences in inflammatory markers (IL-6, IL-10, IL-1α, IFN-γ, TNF-α)(mother)
Concentration differences in glucose independent peptide (GIP) (mother)
Concentration differences in glucagon like peptide 1 (GLP-1) (mother)
Concentration differences in glucagon (mother)
Concentration differences in c-peptide (mother)
Concentration differences in amino acids (AA) (mother)
Concentration differences in progesterone (mother)
Concentration differences in steroid hormone binding protein (SHBP) (mother)
Concentration differences in carboxy-terminal collagen crosslinks (CTx) (mother)
Concentration differences in osteocalcin (OCN) (mother)
Concentration differences in Pro-collagen I, N-term. pro-peptide (PINP) (mother)
Concentration differences in Human chorionic gonadotropin (HCG) (mother)
Concentration differences in CD163 (mother)
Concentration differences in estradiol (mother)
Concentration differences in hb1ac (mother)
Concentration differences in lipids (cholesterol, triglyceride) (mother)
Concentration differences in Insulin (cord blood, offspring)
Concentration differences in c-peptide (cord blood, offspring)
Concentration differences in glucagon (cord blood, offspring)
Concentration differences in glucose (cord blood, offspring)
Concentration differences in lactate (cord blood, offspring)
Differences in pH (cord blood, offspring)
Measurement of acidity of the blood. Standard measurement performed on a sample of cord blood when a baby is delivered to evaluate possible oxygen deficiency during delivery.
non-targeted metabolomics analysis (cord blood, offspring)
Analysis generating metabolites from pathways on amino acids, peptides, carbohydrates, lipids and energy measured in folds rise/fall in when comparing placebo with whey
DNA methylations measured with 850K-Illumina Infinium assay.
Differentially methylated sites or regions associated with the intervention will be assessed.
RNA-Seq transcriptome profiling
Up and down-regulated genes associated with the intervention will be assessed
Body fat (offspring)
Sum of skinfolds measured with a caliper
Birth weight (offspring)
Head circumference (offspring)
abdominal circumference (offspring)
Length (offspring)
Number of infants with icterus
Apgar-score
Apgar score, range from 0-10, with the higher score the better outcome.
number of patients needing early feeding
Number of days admitted immediately after delivery
Number of infants with hypoglycemia
Weight of placenta
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04856800
Brief Title
Pre-meal Consumption of Whey in Gestational Diabetes Mellitus From Diagnosis to Delivery
Official Title
Pre-meal Consumption of Whey in Gestational Diabetes Mellitus From Diagnosis to Delivery
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The main objective of the study is to investigate the metabolic effects of whey protein (whey protein isolate, WPI, (Lacprodan® ISO.Water. from Arla Foods Ingredients) compared with placebo when consumed by women with gestational diabetes mellitus (GDM) from diagnosis (around gestational week 28) to delivery. Any changes in substrate metabolism and energy expenditure using indirect calorimetry will also be investigated. Differences in hunger and satiety parameters as well as blood pressure and gestational weight gain will also be assessed. Furthermore, analysis on the glucose response when the women consume the intervention (whey or placebo) at home in their own environment 30 minutes before breakfast at time of diagnosis (earliest week 28) and week 36 (four days following each time point) will be made. The women will be monitored with continuous glucose monitors, activity monitors and all meals will be provided for two days following the study days in the laboratory. At delivery cord blood will be sampled for analysis on metabolic parameters and investigations on epigenetics/DNA methylations. Complications to the delivery, neonatal outcomes, anthropometrics of the child will also be assessed. Breast milk composition will also be analyzed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Whey
Arm Type
Experimental
Arm Description
Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey
Intervention Description
20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
The placebo contains <1 kcal and 0 g protein
Primary Outcome Measure Information:
Title
Maternal glycemic variability (GV)
Description
The Coefficient of Variation, power: n = 50
Time Frame
24 hours
Title
Maternal glycemic variability (GV)
Description
Interquartile range (IQR), power n = 40
Time Frame
24 hours
Title
Maternal glycemic variability (GV)
Description
Standard deviation (SD), power n = 18
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
24 hours interstitial fluid glucose measures
Description
Continuous glucose monitoring
Time Frame
24 hours
Title
mean glucose
Description
Continuous glucose monitoring
Time Frame
24 hours
Title
maximum glucose
Description
Continuous glucose monitoring
Time Frame
24 hours
Title
Interstitial fluid glucose concentrations
Description
Continuous glucose monitoring
Time Frame
3 hours following breakfast
Title
Total energy expenditure
Description
Measured with a combined accelerometer and heart rate monitor, reported in kcal
Time Frame
24 hours
Title
Activity energy expenditure
Description
Measured with a combined accelerometer and heart rate monitor, reported in kcal
Time Frame
24 hours
Title
Activity count
Description
Measured with a combined accelerometer and heart rate monitor, reported in counts
Time Frame
24 hours
Title
Heart rate
Description
Measured with a combined accelerometer and heart rate monitor, reported in beats per minute
Time Frame
24 hours
Title
Resting energy expenditure (REE) (Resting Metabolic Rate)
Description
Indirect calorimetry
Time Frame
Performed for 20 minutes
Title
Respiratory quotient (RQ)
Description
Indirect calorimetry
Time Frame
Performed for 20 minutes
Title
Oxidation rates of lipid, carbohydrate and protein
Description
Indirect calorimetry
Time Frame
Performed for 20 minutes
Title
Diet diary
Description
Total energy intake, composition of macronutrients
Time Frame
24 hours
Title
Self-reported appetite
Description
Questionnaire: A numerical rating scale ranging from "not at all = 0" to "extremely = 10" will be used to assess Hunger, Fullness, Satiety, Desire, Prospective consumption (Quantity).
Time Frame
3,5 hours following intake of whey/placebo at diagnosis, week 32 and week 36
Title
Body Mass Index
Description
weight and height will be combined to report BMI in kg/m^2
Time Frame
at diagnosis, week 32 and week 36
Title
Gestational weight change
Time Frame
at diagnosis, week 32 and week 36
Title
Medications
Description
number of participants prescribed insulin, dose of insulin, time to insulin. Methyldopa, nifidipin or labetalol (medication to lower blood pressure)
Time Frame
from diagnosis to delivery
Title
Pregnancy data
Description
Number of participants with hypertension, preeclampsia, maternal weight gain
Time Frame
from diagnosis to delivery
Title
Delivery data
Description
Number of patients with cesarean section, shoulder dystocia, induction of labour
Time Frame
at delivery
Title
Non-targeted metabolomics will be performed on a sample of breast milk using Nuclear Magnetic Resonance
Description
Analysis generating metabolites from pathways on amino acids, peptides, carbohydrates and lipids measured in folds increase/decrease when comparing placebo with whey
Time Frame
Day 1 postpartum
Title
Blood pressure
Description
Systolic and diastolic blood pressure
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Insulin like growth factor I (IGF-1) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in IGF-binding protein 3 (IGFBP-3) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in IGF-binding protein 1 (IGFBP-1) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in FGF-21 (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Leptin (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Adiponectin (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in CRP (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Prolactin (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Cortisol (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Insulin (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Free Fatty Acids (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in lactate (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in grehlin (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in inflammatory markers (IL-6, IL-10, IL-1α, IFN-γ, TNF-α)(mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in glucose independent peptide (GIP) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in glucagon like peptide 1 (GLP-1) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in glucagon (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in c-peptide (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in amino acids (AA) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in progesterone (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in steroid hormone binding protein (SHBP) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in carboxy-terminal collagen crosslinks (CTx) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in osteocalcin (OCN) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Pro-collagen I, N-term. pro-peptide (PINP) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Human chorionic gonadotropin (HCG) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in CD163 (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in estradiol (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in hb1ac (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in lipids (cholesterol, triglyceride) (mother)
Time Frame
at diagnosis, week 32 and week 36
Title
Concentration differences in Insulin (cord blood, offspring)
Time Frame
at delivery
Title
Concentration differences in c-peptide (cord blood, offspring)
Time Frame
at delivery
Title
Concentration differences in glucagon (cord blood, offspring)
Time Frame
at delivery
Title
Concentration differences in glucose (cord blood, offspring)
Time Frame
at delivery
Title
Concentration differences in lactate (cord blood, offspring)
Time Frame
at delivery
Title
Differences in pH (cord blood, offspring)
Description
Measurement of acidity of the blood. Standard measurement performed on a sample of cord blood when a baby is delivered to evaluate possible oxygen deficiency during delivery.
Time Frame
at delivery
Title
non-targeted metabolomics analysis (cord blood, offspring)
Description
Analysis generating metabolites from pathways on amino acids, peptides, carbohydrates, lipids and energy measured in folds rise/fall in when comparing placebo with whey
Time Frame
at delivery
Title
DNA methylations measured with 850K-Illumina Infinium assay.
Description
Differentially methylated sites or regions associated with the intervention will be assessed.
Time Frame
at delivery
Title
RNA-Seq transcriptome profiling
Description
Up and down-regulated genes associated with the intervention will be assessed
Time Frame
at delivery
Title
Body fat (offspring)
Description
Sum of skinfolds measured with a caliper
Time Frame
at delivery
Title
Birth weight (offspring)
Time Frame
at delivery
Title
Head circumference (offspring)
Time Frame
at delivery
Title
abdominal circumference (offspring)
Time Frame
at delivery
Title
Length (offspring)
Time Frame
at delivery
Title
Number of infants with icterus
Time Frame
through hospital admission immediately after delivery
Title
Apgar-score
Description
Apgar score, range from 0-10, with the higher score the better outcome.
Time Frame
at delivery
Title
number of patients needing early feeding
Time Frame
through hospital admission immediately after delivery
Title
Number of days admitted immediately after delivery
Time Frame
through hospital admission immediately after delivery
Title
Number of infants with hypoglycemia
Time Frame
at delivery
Title
Weight of placenta
Time Frame
at delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
GDM (OGTT level of blood glucose ≥ 9 mmol/L)
Normal blood pressure
Age > 18 years
Exclusion Criteria:
Special dietary regimes > 1 month at time of inclusion e.g. ketogenic diet
Daily intake of protein supplements
Milk allergy or phenylketonuria
Medication with effect on glucose metabolism e.g. steroids
Do not speak or understand Danish
Twin pregnancy
PCOS
PI finds the patient unfit (like mental illness, too nervous or other)
Severe chronic illness
Severe nausea/vomiting
Non-breakfast eaters
Celiac disease
The initiation of insulin treatment during the trial will not lead to exclusion from the trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stine B Smedegaard, MD
Phone
20714671
Email
stinesmedegaard@clin.au.dk
Facility Information:
Facility Name
Medicinsk forskningslaboratorium for Diabetes og Hormonsygdomme og Steno Diabetes Center Aarhus (M-lab), Aarhus universitetshospital
City
Aarhus
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per G Ovesen, Professor
12. IPD Sharing Statement
Learn more about this trial
Pre-meal Consumption of Whey in Gestational Diabetes Mellitus From Diagnosis to Delivery
We'll reach out to this number within 24 hrs